Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

Lignende værker

• Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
  af: Chong, G, et al.
  Udgivet: (2005)
• Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
  af: Sumpter, K, et al.
  Udgivet: (2005)
• Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
  af: Rao, S, et al.
  Udgivet: (2008)
• Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
  af: Price, T J, et al.
  Udgivet: (2015)
• Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
  af: Chong, G, et al.
  Udgivet: (2006)